The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based ... both have a long duration of action, allowing once-daily administration.

Metabolic control can be improved markedly by administration of exogenous GLP-1, but the ... that inhibit DPP-4, thereby prolonging the duration of endogenous incretin action, have, therefore ...

Sarah M. Baxter, from Queen’s University Belfast in Northern Ireland, and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated ...